Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mediwound Ltd Ord Sh (NQ: MDWD )

8.910 -0.050 (-0.56%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 28,029
Open 9.000
Bid (Size) 8.900 (11)
Ask (Size) 9.090 (5)
Prev. Close 8.960
Today's Range 8.900 - 9.100
52wk Range 8.050 - 15.72
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Earnings Scheduled For May 30, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report earnings for its first quarter. 
Via Benzinga
Recap: MediWound Q1 Earnings
 
Via Benzinga

Performance

YTD
-32.96%
-32.96%
1 Month
-17.88%
-17.88%
3 Month
-26.30%
-26.30%
6 Month
-11.61%
-11.61%
1 Year
-31.57%
-31.57%

More News

Read More
MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update
From MediWound Ltd.
Via GlobeNewswire
Earnings Outlook For MediWound
Via Benzinga
MediWound to Report First Quarter 2023 Financial Results
From MediWound Ltd.
Via GlobeNewswire
5 Analysts Have This to Say About MediWound
Via Benzinga
Preview: MediWound's Earnings
Via Benzinga
Cowen & Co. Maintains Outperform Rating for MediWound: Here's What You Need To Know
Via Benzinga
MediWound Announces an Additional $10 Million Award from BARDA
From MediWound Ltd.
Via GlobeNewswire
MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023
From MediWound Ltd.
Via GlobeNewswire
MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
From MediWound Ltd.
Via GlobeNewswire
FDA Approves MediWound's NexoBrid For Burn Treatment
Via Benzinga
MediWound Expands its Global Leadership Team to Help Drive Company’s Future Growth
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
From MediWound Ltd.
Via GlobeNewswire
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market
From MediWound Ltd.
Via GlobeNewswire
Starbucks To Rally 11%? Here Are 10 Other Analyst Forecasts For Wednesday
Via Benzinga
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
From MediWound Ltd.
Via GlobeNewswire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Via Benzinga
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
From MediWound Ltd.
Via GlobeNewswire
MediWound Strengthens European Presence of NexoBrid®
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
From MediWound Ltd.
Via GlobeNewswire
MediWound Expands Global Presence as NexoBrid® Gains Approval in India
From MediWound Ltd.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.